Abstract
Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibro-proliferative disorder of unknown etiology, with no effective treatment regimen, and a median survival of just 3–5 years following diagnosis [1]. Pulmonary Hypertension (PH) often complicates IPF and is associated with higher mortality. Augmentation of endogenous natriuretic peptide (NP) stimulated cGMP, using a neutral endopeptidase inhibitor (NEPi) in combination with a phosphodiesterase 5 inhibitor (PDE5i), synergistically prevents pathogenesis in a hypoxic model of PH [2]. Herein, we assessed the efficacy of this novel NEPi/ PDE5i combination therapy in a model of pulmonary fibrosis.
Highlights
Idiopathic pulmonary fibrosis (IPF) is a progressive fibro-proliferative disorder of unknown etiology, with no effective treatment regimen, and a median survival of just 3–5 years following diagnosis [1]
Bleo treatment caused a significant rise in right ventricular systolic pressure (RSVP) in WT mice that was not reduced by either sildenafil or ecadotril alone, but significantly inhibited by the combination (Figure 1)
Bleo administration resulted in right ventricular hypertrophy (RVH); this was prevented by treatment with sildenafil, ecadotril or the combination (RV/LV+S; Control: 0.2486±0.005, Bleo: 0.3054±0.0177, Bleo+sildenafil: 0.258±0.006*, Bleo+ecadotril: 0.261±0.008*, Bleo+combination: 0.247±0.008*; *P
Summary
Idiopathic pulmonary fibrosis (IPF) is a progressive fibro-proliferative disorder of unknown etiology, with no effective treatment regimen, and a median survival of just 3–5 years following diagnosis [1]. Pulmonary Hypertension (PH) often complicates IPF and is associated with higher mortality. Augmentation of endogenous natriuretic peptide (NP) stimulated cGMP, using a neutral endopeptidase inhibitor (NEPi) in combination with a phosphodiesterase 5 inhibitor (PDE5i), synergistically prevents pathogenesis in a hypoxic model of PH [2]. We assessed the efficacy of this novel NEPi/ PDE5i combination therapy in a model of pulmonary fibrosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.